Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -25.20% is in line with its 2-year average of -25.00%, around the middle of its 2-year range (-29.63%–-22.01%).
As of the fiscal period ended Tuesday, June 30, 2026. 5.04% above its 12-month average of -26.53%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -25.20%.
RETURN ON EQUITY (ROE)
-25.20%
RETURN ON EQUITY (ROE) AVG TTM
-26.53%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+5.04%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 745 covered companies
CURRENT VS SECTOR MEDIAN
+40.02%
vs the sector median at left
BioAge Labs Inc.
Market Cap
$236.10M
Return on Equity (ROE)
-25.20%
TTM Avg
-26.53%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$235.98M
Return on Equity (ROE)
8.59%
TTM Avg
10.64%
3Y Avg
12.16%
5Y Avg
12.16%
Market Cap
$234.93M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
Market Cap
$236.84M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$234.54M
Return on Equity (ROE)
-1.67%
TTM Avg
19.58%
3Y Avg
23.42%
5Y Avg
29.49%
Market Cap
$237.69M
Return on Equity (ROE)
-31.55%
TTM Avg
-30.05%
3Y Avg
-33.97%
5Y Avg
-37.95%
Market Cap
$238.34M
Return on Equity (ROE)
-59.27%
TTM Avg
-136.66%
3Y Avg
-113.26%
5Y Avg
-53.68%
Market Cap
$239.30M
Return on Equity (ROE)
31.90%
TTM Avg
-385.06%
3Y Avg
-191.20%
5Y Avg
-142.10%
Market Cap
$232.52M
Return on Equity (ROE)
-43.11%
TTM Avg
-35.75%
3Y Avg
-28.47%
5Y Avg
-12.53%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BioAge Labs Inc. (BIOA) | $236.10M | -25.20% | -26.53% | N/A | N/A |
| Utah Medical Products, Inc. (UTMD)vs › | $235.98M | 8.59% | 10.64% | 12.16% | 12.16% |
| InflaRx N.V. (IFRX)vs › | $234.93M | -27.27% | -92.43% | -64.95% | -57.80% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $236.84M | -118.58% | 62.37% | -376.78% | -340.60% |
| SIGA Technologies, Inc. (SIGA)vs › | $234.54M | -1.67% | 19.58% | 23.42% | 29.49% |
| High Tide Inc. (HITI)vs › | $237.69M | -31.55% | -30.05% | -33.97% | -37.95% |
| Invivyd, Inc. (IVVD)vs › | $238.34M | -59.27% | -136.66% | -113.26% | -53.68% |
| Q32 Bio Inc. (QTTB)vs › | $239.30M | 31.90% | -385.06% | -191.20% | -142.10% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $232.52M | -43.11% | -35.75% | -28.47% | -12.53% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $240.34M | N/A | -125.28% | -42.20% | -43.41% |
ROE
-25.2%
ROA
-23.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -25.20% |
| 2026-03-31 | -23.72% |
| 2025-12-31 | -29.63% |
| 2025-09-30 | -27.32% |
| 2025-06-30 | -26.81% |
| 2025-03-31 | -22.69% |
| 2024-12-31 | -22.01% |
| 2024-09-30 | -22.61% |
